Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure: Insight From the Studies Of Left Ventricular Dysfunction (SOLVD)

Background—Diabetes mellitus is a predictor of morbidity and mortality in patients with heart failure. The effect of angiotensin-converting enzyme (ACE) inhibitors on the prevention of diabetes in patients with left ventricular dysfunction is unknown. The aim of this retrospective study was to assess the effect of the ACE inhibitor enalapril on the incidence of diabetes in the group of patients from the Montreal Heart Institute enrolled in the Studies of Left Ventricular Dysfunction (SOLVD). Methods and Results—Clinical charts were evaluated for fasting plasma glucose (FPG) levels by blinded reviewers. A diagnosis of diabetes was made when a FPG ≥126 mg/dL (7 mmol/L) was found at 2 visits (follow-up, 2.9±1.0 years). Of the 391 patients enrolled at the Montreal Heart Institute, 291 were not diabetic (FPG <126 mg/dL without a history of diabetes), 153 of these were on enalapril and 138 were on placebo. Baseline characteristics were similar in the 2 groups. Forty patients developed diabetes during follow-up, 9 (5.9%) in the enalapril group and 31 (22.4%) in the placebo group (P <0.0001). By multivariate analysis, enalapril remained the most powerful predictor for risk reduction of developing diabetes (hazard ratio, 0.22; 95% confidence intervals, 0.10 to 0.46;P <0.0001). The effect of enalapril was striking in the subgroup of patients with impaired FPG (110 mg/dL [6.1 mmol/L] ≤FPG <126 mg/dL) at baseline: 1 patient (3.3%) in the enalapril group versus 12 (48.0%) in the placebo group developed diabetes (P <0.0001). Conclusions—Enalapril significantly reduces the incidence of diabetes in patients with left ventricular dysfunction, especially those with impaired FPG.

[1]  Salim Yusuf,et al.  Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. , 1990, The American journal of cardiology.

[2]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[3]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[4]  E. G. Erdös,et al.  A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. , 1970, Biochimica et biophysica acta.

[5]  M. Shichiri,et al.  Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: Bradykinin may improve insulin resistance in dogs and humans , 1994, Diabetologia.

[6]  S. Yusuf,et al.  Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. , 1996, The American journal of cardiology.

[7]  G. Paolisso,et al.  Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. , 1991, Metabolism: clinical and experimental.

[8]  A. Golay,et al.  Insulin Sensitivity in Obese Hypertensive Dyslipidemic Patients Treated with Enalapril or Atenolol , 1995, Journal of cardiovascular pharmacology.

[9]  N. Chaturvedi Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.

[10]  H. Okamura,et al.  The Effect of Prostaglandin , 1972 .

[11]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[12]  D. Hardie,et al.  Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. , 2000, Diabetes.

[13]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[14]  C. Berne,et al.  Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats , 1998, Diabetologia.

[15]  K. Kanmatsuse,et al.  Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. , 1994, Hypertension.

[16]  H. Parving,et al.  Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive Type 1 (insulin-dependent) diabetic patients with background retinopathy , 1989, Diabetologia.

[17]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[18]  E. Newsholme,et al.  The effect of prostaglandins E1, E2 and F2 alpha and indomethacin on the sensitivity of glycolysis and glycogen synthesis to insulin in stripped soleus muscles of the rat. , 1985, The Biochemical journal.

[19]  C. Berne,et al.  A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. , 1989, The New England journal of medicine.

[20]  M. Nieminen,et al.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.

[21]  S. Yusuf,et al.  Ramipril and the development of diabetes. , 2001, JAMA.

[22]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[23]  J. Nadler,et al.  Evidence that nitric oxide increases glucose transport in skeletal muscle. , 1997, Journal of applied physiology.

[24]  S. Jacob,et al.  Differential effect of chronic treatment with two beta‐blocking agents on insulin sensitivity: the carvedilol‐metoprolol study , 1996, Journal of hypertension.

[25]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[26]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[27]  S. Yusuf,et al.  Natural history and patterns of current practice in heart failure , 1993 .

[28]  D. Sacks,et al.  The pathogenesis of type II diabetes mellitus. A polygenic disease. , 1996, American journal of clinical pathology.

[29]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[30]  S. Jacob,et al.  ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[31]  T. A. Schultz,et al.  Glucose delivery: a modulator of glucose uptake in contracting skeletal muscle. , 1977, The American journal of physiology.